KR20240101622A - 비아편유사제에 의해 조절되는 호흡 억제의 치료 방법 - Google Patents

비아편유사제에 의해 조절되는 호흡 억제의 치료 방법 Download PDF

Info

Publication number
KR20240101622A
KR20240101622A KR1020247018353A KR20247018353A KR20240101622A KR 20240101622 A KR20240101622 A KR 20240101622A KR 1020247018353 A KR1020247018353 A KR 1020247018353A KR 20247018353 A KR20247018353 A KR 20247018353A KR 20240101622 A KR20240101622 A KR 20240101622A
Authority
KR
South Korea
Prior art keywords
substituted
hours
compound
minutes
bond
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247018353A
Other languages
English (en)
Korean (ko)
Inventor
조셉 페르골리찌
토마스 밀러
알프레드 슈웨이커트
Original Assignee
에날레어 테라퓨틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에날레어 테라퓨틱스 인크. filed Critical 에날레어 테라퓨틱스 인크.
Publication of KR20240101622A publication Critical patent/KR20240101622A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247018353A 2021-11-02 2022-11-02 비아편유사제에 의해 조절되는 호흡 억제의 치료 방법 Pending KR20240101622A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163274722P 2021-11-02 2021-11-02
US63/274,722 2021-11-02
PCT/US2022/048669 WO2023081185A1 (en) 2021-11-02 2022-11-02 Methods of treating respiratory depression modulated by a non-opioid agent

Publications (1)

Publication Number Publication Date
KR20240101622A true KR20240101622A (ko) 2024-07-02

Family

ID=86147248

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247018353A Pending KR20240101622A (ko) 2021-11-02 2022-11-02 비아편유사제에 의해 조절되는 호흡 억제의 치료 방법

Country Status (10)

Country Link
US (2) US12138267B2 (https=)
EP (1) EP4426308A4 (https=)
JP (1) JP2024540198A (https=)
KR (1) KR20240101622A (https=)
CN (1) CN118488840A (https=)
AU (1) AU2022380482A1 (https=)
CA (1) CA3236586A1 (https=)
MX (1) MX2024005389A (https=)
TW (1) TW202333730A (https=)
WO (1) WO2023081185A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025511227A (ja) * 2022-04-01 2025-04-15 エナラーレ セラピューティクス インコーポレイテッド 呼吸器刺激性経鼻製剤
US20230414624A1 (en) * 2022-06-24 2023-12-28 Enalare Therapeutics Inc. Methods of treating neurological ventilatory insufficiency

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4508715A (en) 1981-07-01 1985-04-02 University Of Georgia Research Foundation, Inc. Antagonism of central nervous system drugs by the administration of 4-aminopyridine alone or in combination with other drugs
AU2011322147A1 (en) * 2010-10-26 2013-04-18 Alpharma Pharmaceuticals, Llc Formulations and methods for attenuating respiratory depression induced by opioid overdose
US20120295911A1 (en) 2010-11-29 2012-11-22 Galleon Pharmaceuticals, Inc. Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases
AU2011336764B2 (en) * 2010-11-29 2017-02-23 Galleon Pharmaceuticals, Inc. Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases
SG11201503505QA (en) 2012-11-15 2015-06-29 Galleon Pharmaceuticals Inc Novel orally bioavailable breathing control modulating compounds, and methods of using same
WO2016007729A1 (en) 2014-07-09 2016-01-14 Lightlake Therapeutics Inc. Co-packaged drug products
HK1245079A1 (zh) 2015-06-30 2018-08-24 纽拉德有限公司 新颖呼吸控制调节化合物以及其制备和使用方法
ES2925951T3 (es) 2015-07-22 2022-10-20 John Hsu Composición que comprende un agente terapéutico y un estimulante respiratorio y métodos para su uso
EP3833346A4 (en) 2018-08-08 2022-08-03 Torralva Medical Therapeutics LLC Compositions for opiate and opioid prevention and reversal, and methods of their use

Also Published As

Publication number Publication date
AU2022380482A1 (en) 2024-05-16
JP2024540198A (ja) 2024-10-31
US20250032496A1 (en) 2025-01-30
EP4426308A1 (en) 2024-09-11
CA3236586A1 (en) 2023-05-11
US20230140606A1 (en) 2023-05-04
EP4426308A4 (en) 2025-09-03
MX2024005389A (es) 2024-07-09
US12138267B2 (en) 2024-11-12
WO2023081185A1 (en) 2023-05-11
TW202333730A (zh) 2023-09-01
CN118488840A (zh) 2024-08-13

Similar Documents

Publication Publication Date Title
US20250032496A1 (en) Methods of treating respiratory depression modulated by a non-opioid agent
US20250031718A1 (en) Nicotinamide adenine dinucleotide (nad) compositions, methods of manufacturing thereof, and methods of use thereof
US20250114370A1 (en) Methods and compositions for treating drug overdose
KR20240167901A (ko) 호흡 자극제 비강 제형
KR20240150426A (ko) 비경구 호흡 자극제 제형
US20230414624A1 (en) Methods of treating neurological ventilatory insufficiency
US20240238303A1 (en) Large-conductance potassium channel modulators, compositions thereof, methods of manufacturing thereof, and methods of use thereof
TW202529771A (zh) 用於治療藥物過量的方法及組合物
WO2022234336A1 (en) Nicotinamide adenine dinucleotide (nad) compositions, methods of manufacturing thereof, and methods of use thereof
CN118829433A (zh) 呼吸刺激剂肠胃外制剂

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000